After a 2024 in which AbbVie’s Skyrizi boasted the highest TV drug ad spending outlay on seven of our monthly roundups—and took second place in four more—the immunology med has seen that dominance ...
Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...
Spot and Tubular data show prescription immunology brands continued to dominate TV, while seasonal OTC brands found scale on ...
Skyrizi, Rinvoq and Tremfya claimed the top three spots in the linear TV rankings in March. Seasonal OTC brands like Vicks and Afrin stayed highly visible, following the cold and flu wave. News ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results